Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

Executive Summary

CDER Director Woodcock says it may not be necessary for the ANDA first-cycle approval rate to approach that for NDAs, but lowering the number of cycles to two would be desirable.


Related Content

Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review
FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace
FDA Exploring Whether Public Shaming Can Stop REMS Abuses
ANDA Approvals Break Record, May Set New Normal
Generic Drugs: First-Cycle Review Times Improve, But Hundreds Of ANDAs Still Pending
FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit
ANDA Approval Times Get Optimistic Estimate In Budget Request
ANDA Submissions Continue Yo-Yo Pattern, Unlike Approvals
Generic Application Quality Showing Signs Of Improvement
First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts